Fulcrum Therapeutics, Inc.

FULC Healthcare Biotechnology

Fulcrum Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $80.0 million, up 2,752.0% from fiscal 2023. In the quarter to June 2026, EPS fell 21.4% and free cash flow fell 13.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.65 0.02 −0.54%
Market cap
$280.0M
P/E
0.0×
Fwd P/E
−9.4×
Dividend yield
—
F-score
5/9
Altman Z
8.22
Beneish M
21.24
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
17.70 27.40 34.33 31.35
Net Debt/EBITDA
9.33 15.77 15.26 10.96
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.23) (0.27) (0.25) (0.21)
Book value per Share
3.17 5.51 4.37 4.07
Free Cash Flow
(14.28) (16.96) (18.76) (15.70)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates